BridGene Biosciences Achieves the Second Preclinical Milestone in Takeda Collaboration
- Monday, August 28, 2023, 7:11
- Business
- Add a comment
IMTAC™ platform identifies novel targets and small molecules for the development of drugs to treat a broad spectrum of neurological disorders SAN JOSE, Calif., Aug. 28, 2023 /PRNewswire/ — BridGene Biosciences, Inc., a biotechnology company that uses proprietary chemoproteomics…
About the Author
adminasapcorp has written 39311 stories on this site.